Matt Chrysler

Matt Chrysler's Title

Matt Chrysler is the Head of Portfolio & Alliance Management at TRexBio. In this pivotal role, he leverages his extensive experience to manage and optimize the company's portfolio of projects and strategic alliances. His expertise is crucial in aligning TRexBio’s objectives with its strategic partnerships, ensuring the successful delivery of innovative biotech solutions.

Matt Chrysler's Company

Matt Chrysler joined TRexBio in 2019, bringing with him a wealth of knowledge from his extensive career in biotechnology. TRexBio is known for its cutting-edge research and development in the biotech sector, focusing on novel therapies and advancements. With Matt's leadership in portfolio and alliance management, TRexBio aims to accelerate its growth and impact in the industry.

Matt Chrysler's Experience

Matt Chrysler has accumulated over 15 years of portfolio and commercial experience across both emerging and large biotechnology companies. Prior to joining TRexBio, he played a crucial role at Ultragenyx, where he led New Product Planning and was the Global Commercial Lead for several late-stage programs, including the launch preparations for Crysvita. His earlier career at Genentech further honed his skills in portfolio management, corporate strategy, and brand management. Matt's career began as a Management Consultant at ZS Associates, giving him a strong foundation in strategic planning and execution.

Matt Chrysler's Education and Expertise

Matt Chrysler's educational background is both diverse and robust. He holds an MBA and an MS in biochemistry from Georgetown University, equipping him with a unique blend of scientific and business acumen. Additionally, he earned a BS in microbiology from the University of Washington. This combination of education and expertise allows Matt to navigate complex biotech landscapes effectively, making strategic decisions that drive innovation and growth.

Matt Chrysler's Achievements

Throughout his career, Matt Chrysler has achieved significant milestones. At Ultragenyx, he was instrumental in driving early-stage pipeline strategy decisions for potential gene therapy, biologic, and small molecule therapeutics. His leadership in the launch preparations for Crysvita, in collaboration with a global pharmaceutical partner, stands out as a notable achievement. These accomplishments highlight Matt's ability to lead complex projects and deliver results that contribute to the advancement of biotechnology.